<DOC>
	<DOCNO>NCT00955175</DOCNO>
	<brief_summary>RATIONALE : Specialized radiation therapy delivers high dose radiation directly tumor short period time may kill tumor cell cause less damage normal tissue . PURPOSE : This phase II trial study side effect hypofractionated 3-dimensional radiation therapy see well work treat patient newly diagnose stage I , stage II , stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Hypofractionated 3-Dimensional Radiation Therapy Treating Patients With Newly Diagnosed Stage I , Stage II , Stage III Non-Small Cell Lung Cancer . ICORG 99-09</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate acute long-term radio-induced toxicity ( organ ) hypofractionated 3-dimensional conformal radiotherapy patient newly diagnose stage I-III non-small cell lung cancer . Secondary - To assess radiological tumor response rate 3 month completion radiotherapy . - To assess actuarial freedom thoracic progression rate . OUTLINE : Patients stratify accord combine lung volume 25 Gy ( ≤ 30 % v &gt; 30 % ) . Patients assign 1 3 treatment group . - Group 1 : Patients undergo hypofractionated 3-dimensional conformal radiotherapy 5 day week 24 fraction ( total 72 Gy ) . - Group 2 : Patients undergo hypofractionated 3-dimensional conformal radiotherapy 5 day week 22 fraction ( total 66 Gy ) . - Group 3 : Patients undergo hypofractionated 3-dimensional conformal radiotherapy 5 day week 20 fraction ( total 60 Gy ) . After completion study treatment , patient follow every 3 month 2 year every 6 month thereafter .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm newly diagnose nonsmall cell lung cancer meet 1 follow stage criterion : Stage I II disease Medically inoperable patient refuse surgery Stage IIIA IIIB disease ( pleural effusion ) Radiation dose parameter must satisfy require study dosevolume constraint PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Weight loss ≤ 10 % within 3 month diagnosis No malignancy within past 5 year , except nonmelanoma skin cancer No clinically significant cardiovascular disease ( e.g. , hypertension [ blood pressure &gt; 150/100 mm Hg ] , myocardial infarction stroke within past 6 month , unstable angina ) PRIOR CONCURRENT THERAPY : No concurrent chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>